Randomised, double-blind n-of-1 trial in one child with a gain-of-function KCNC1 variant: fluoxetine vs placebo was associated with a 6.61-point motor score gain (95% CrI -0.53 to 14.78); it was well tolerated, with possible withdrawal irritability.
RCTn = 1
Jha et al. An n-of-1 gene-directed drug repurposing trial for an ultrarare genetic condition